PYC Therapeutics Advances Optic Atrophy Drug to Multiple-Dose Study After Safety Clearance; Shares Up 7%

MT Newswires Live

Apr 15

PYC Therapeutics (ASX:PYC) has been cleared by the safety review committee to advance PYC-001 candidate into a multiple ascending dose study in patients with autosomal dominant optic atrophy (ADOA), following positive four-week safety and tolerability results from the 60 microgram single ascending dose trial, according to a Wednesday filing with the Australian bourse.

The company is currently assessing repeat dosing in ADOA patients to evaluate safety and preliminary efficacy, aiming to establish clinical proof of concept before initiating a global registrational trial to support a new drug application, the filing said.

The results from the ongoing phase one and two multiple ascending dose study will be presented throughout 2026 and 2027, the filing added.

The company's shares rose 7% in recent Wednesday trade.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/news/2627748644"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2627748644\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2627748644?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-15 10:53","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2627748644","market":"sh","top_or_hot":-1,"title":"PYC Therapeutics Advances Optic Atrophy Drug to Multiple-Dose Study After Safety Clearance; Shares Up 7%","media":"MT Newswires Live","content":"<html><body><p> PYC <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (ASX:PYC) has been cleared by the safety review committee to advance PYC-001 candidate into a multiple ascending dose study in patients with autosomal dominant optic atrophy (ADOA), following positive four-week safety and tolerability results from the 60 microgram single ascending dose trial, according to a Wednesday filing with the Australian bourse.</p><p>The company is currently assessing repeat dosing in ADOA patients to evaluate safety and preliminary efficacy, aiming to establish clinical proof of concept before initiating a global registrational trial to support a new drug application, the filing said.</p><p>The results from the ongoing phase one and two multiple ascending dose study will be presented throughout 2026 and 2027, the filing added.</p><p>The company's shares rose 7% in recent Wednesday trade.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>PYC Therapeutics Advances Optic Atrophy Drug to Multiple-Dose Study After Safety Clearance; Shares Up 7%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPYC Therapeutics Advances Optic Atrophy Drug to Multiple-Dose Study After Safety Clearance; Shares Up 7%\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-04-15 10:53</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> PYC <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (ASX:PYC) has been cleared by the safety review committee to advance PYC-001 candidate into a multiple ascending dose study in patients with autosomal dominant optic atrophy (ADOA), following positive four-week safety and tolerability results from the 60 microgram single ascending dose trial, according to a Wednesday filing with the Australian bourse.</p><p>The company is currently assessing repeat dosing in ADOA patients to evaluate safety and preliminary efficacy, aiming to establish clinical proof of concept before initiating a global registrational trial to support a new drug application, the filing said.</p><p>The results from the ongoing phase one and two multiple ascending dose study will be presented throughout 2026 and 2027, the filing added.</p><p>The company's shares rose 7% in recent Wednesday trade.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2627748644","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2627748644","pubTimestamp":1776221591,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"PYC Therapeutics  has been cleared by the safety review committee to advance PYC-001 candidate into a multiple ascending dose study in patients with autosomal dominant optic atrophy , following positive four-week safety and tolerability results from the 60 microgram single ascending dose trial, according to a Wednesday filing with the Australian bourse.The company is currently assessing repeat dosing in ADOA patients to evaluate safety and preliminary efficacy, aiming to establish clinical proof of concept before initiating a global registrational trial to support a new drug application, the filing said.The results from the ongoing phase one and two multiple ascending dose study will be presented throughout 2026 and 2027, the filing added.The company's shares rose 7% in recent Wednesday trade.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","BK7067":"生物科技","LENZ":"Therapeutics","BK4539":"次新股","PYC.AU":"PYC THERAPEUTICS LTD","BK4139":"生物科技"},"translate_title":"PYC Therapeutics在安全许可后将视神经萎缩药物推进至多剂量研究；股价上涨7%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LENZ":1.5,"PYC.AU":1},"content_text":"PYC Therapeutics (ASX:PYC) has been cleared by the safety review committee to advance PYC-001 candidate into a multiple ascending dose study in patients with autosomal dominant optic atrophy (ADOA), following positive four-week safety and tolerability results from the 60 microgram single ascending dose trial, according to a Wednesday filing with the Australian bourse.The company is currently assessing repeat dosing in ADOA patients to evaluate safety and preliminary efficacy, aiming to establish clinical proof of concept before initiating a global registrational trial to support a new drug application, the filing said.The results from the ongoing phase one and two multiple ascending dose study will be presented throughout 2026 and 2027, the filing added.The company's shares rose 7% in recent Wednesday trade.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}